17 December 2014

KCR Acquires Project Portfolio from Ukrainian CRO AXIS

Warsaw – 17 Dec 2014 – KCR, a European Contract Research Organization (CRO), has recently acquired the whole portfolio of clinical projects from the Ukrainian CRO, AXIS Group Ltd. The acquisition of AXIS trials further strengthens KCR’s presence in Ukraine making the country the most important location for KCR in the region of the Commonwealth of Independent States (CIS).

KCR has a long and successful history of conducting clinical trials in Ukraine since we registered our subsidiary in the country in 2007. With the integration of 15 AXIS projects and almost the entire clinical operations team, we consider KCR as one of the key players in Ukraine in regards to trials execution,” said Mike Jagielski, President & CEO of KCR. "Ukraine, being the second most populated country in the CIS region, presents a favorable market for conducting clinical studies."

Important market drivers are submission requirements adjusted to the EU regulations as well as recent improvements to the regulatory framework regarding new rules on liability insurance as well as guidelines set for bioequivalence studies. The government and local authorities have been strongly committed to make the country a strategic place for trials execution in the CIS region

“Ukraine has  a well-developed system of medical institutions and universities, highly qualified investigators and more and more experienced sites which translates into effective patients recruitment,” adds Tetyana Byelyayeva, General Manager for Ukraine and Georgia, at KCR. “The political situation in the Eastern part of the country does not affect ongoing projects, neither any submission procedures. We conduct all studies according to timelines.”

The acquisition of the AXIS Group Ltd project portfolio has significantly broadened KCR’s operations in Ukraine. With KCR’s long term presence in the country, its excellent base of local contacts, a team of 40 experienced specialists, and an office located in the heart of Kyiv, KCR is well positioned to be a strategic CRO for pharma and biopharma companies.

In an attempt to share its knowledge and experience of working in a broad European context, KCR’s offer includes a service dedicated especially to companies willing to start their studies in Europe, including CEE and CIS regions. The service is aimed at securing comfort and safety of moving operations overseas and retain all advantages of a European execution.

If you would like to learn more about KCR’s services and/or our operations in Ukraine, please contact Joanna Lewandowska, PR & Marketing, at joanna.lewandowska@kcrcro.com. Please include your full contact details in the query.

About KCR
KCR is a Contract Research Organization (CRO) operating across 19 countries in Europe as well as the U.S. The company is a strategic solutions provider for pharmaceutical and biotechnology firms who are looking for a reliable alternative to top tier CROs. Over 300 professionals offer full service capabilities in three main product lines: Trial Execution, Functional Service Provision (FSP) and Late Phase, across a wide range of therapeutic areas. Focusing on knowledge, quality and innovation, KCR and its services supports 12 of the Top 20 Global Pharma companies, as well as biotech firms from Europe, Israel and the U.S. on long standing contracts. For more information please visit: www.kcrcro.com.

KCR: We see human behind every number

Media Contact

Joanna Lewandowska
Associate Director, PR & Marketing
mobile: (+48) 605 053 164
pr@kcrcro.com